Report Includes

• Detailed overview of the colorectal cancer (CRC) therapeutics and corresponding global markets
• Country specific data and analysis for France, Germany, Italy, U.K., Spain, Russia, India, China, Japan, United States, Canada, Middle East and Africa
• Evaluation of market dynamics with a focus on increasing prevalence of colorectal cancer cases, technological advancements in radiology and chemotherapy, and increasing cancer prevention initiatives
• Coverage of some of the significant CRC tests including CT colonography, double-contrast barium enema, and biopsy test and their usability study and future growth potential
• A look into regulatory environment, new products launces and technological advancements, and current strategies within the market
• Company profiles of major manufacturers and suppliers of CRC therapeutic drugs

Report Includes

• An industry analysis of the global market for drug testing technologies within the pharmaceutical industry
• Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
• Statistical information pertaining to drug abuse along with its trends as well as drug classes in key geographic regions
• Information on leading players in the market and their key products
• Sales projections through 2023 for drug of abuse testing markets by sample matrix and geographic regions
• Technological assessment of the current and possible future legislation affecting the market in the U.S. and other emerging economies, and examines the influence of these acts in the development of the industry
• Company profiles of major global players operating within the drug development market

Report Includes

• An introduction to interleukin-2 (IL-2) and identification of its applications
• Insights of the latest trends and technologies in the IL-2 research and development
• Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
• Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile.
• Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
• An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)

Report Includes

• An overview of the global research and development investments in over-the-counter (OTC) drugs and nutraceuticals.
• Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022.
• Discussion of the strategies and plans behind research-and-development activities.
• Estimation of investments in R&D activities in OTC drugs by therapeutic classification, routes of OTC drug administration, companies, institutions, and regions.
• Macro- and micro-level scenarios, insights, and analyses of global R&D initiatives around OTC drugs.
• Company profiles of key players in the industry based on their market shares, product offerings, and regions.

Report Includes

• An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures.
• Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
• Information on the current price and reimbursement landscape, benchmarking statics, and future development opportunities in the pharma industry.
• Case studies of different price and reimbursement strategies for prescription drugs, generics, biosimilars, hospitals, and over-the-counter products.
• Coverage of market dynamics, specifically growth drivers, restraints, and opportunities.
• Comprehensive company profiles of major players in the industry.

Report Includes

• An overview of the global markets for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.
• Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023.
• Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.
• Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity.
• Profiles of major players and leading generics companies.
• A look at recent merger-and-acquisition activity.